The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The chimeric antigen receptor T-cell therapy zamtocabtagene autoleucel (zamto-cel) showed encouraging activity and a favorable safety profile in patients with relapsed or refractory diffuse large
Andrew Lane, MD, PhD, of Dana Farber Cancer Institute, reports the results from a phase 2 trial in tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy in blastic plasmacytoid dendritic cell neoplasms.
The future of registries in the UK came into focus during an afternoon session at SOHO UK with Priyanka Mehta, MBBS, MD, FRCP, FRCPath, a
The US Food and Drug Administration (FDA) approved mosunetuzumab (Lunsumio VELO), a CD20xCD3 bispecific antibody, as a subcutaneous formulation for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Gloria Iacoboni, MD, PhD, a hematologist at Vall d’Hebron University Hospital in Barcelona, Spain, spoke with Dr. James Day, a clinical research training fellow at UCL in London, during this SOHO Insider podcast episode recorded at the inaugural SOHO UK 2026 meeting.
To access the SOHO Career Center click the following link.
